We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Exelixis (EXEL - Free Report) closed the most recent trading day at $24.76, moving +0.2% from the previous trading session. This change outpaced the S&P 500's 0.09% loss on the day. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.16%.
Heading into today, shares of the drug developer had gained 12.06% over the past month, outpacing the Medical sector's gain of 2.75% and the S&P 500's gain of 2.35% in that time.
Wall Street will be looking for positivity from EXEL as it approaches its next earnings report date. The company is expected to report EPS of $0.25, down 32.43% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $215.88 million, up 1.66% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.04 per share and revenue of $930.60 million. These totals would mark changes of -27.27% and +9.17%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for EXEL. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 14.54% lower. EXEL is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, EXEL is currently trading at a Forward P/E ratio of 23.73. For comparison, its industry has an average Forward P/E of 23.32, which means EXEL is trading at a premium to the group.
Also, we should mention that EXEL has a PEG ratio of 0.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.68 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exelixis (EXEL) Gains As Market Dips: What You Should Know
Exelixis (EXEL - Free Report) closed the most recent trading day at $24.76, moving +0.2% from the previous trading session. This change outpaced the S&P 500's 0.09% loss on the day. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.16%.
Heading into today, shares of the drug developer had gained 12.06% over the past month, outpacing the Medical sector's gain of 2.75% and the S&P 500's gain of 2.35% in that time.
Wall Street will be looking for positivity from EXEL as it approaches its next earnings report date. The company is expected to report EPS of $0.25, down 32.43% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $215.88 million, up 1.66% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.04 per share and revenue of $930.60 million. These totals would mark changes of -27.27% and +9.17%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for EXEL. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 14.54% lower. EXEL is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, EXEL is currently trading at a Forward P/E ratio of 23.73. For comparison, its industry has an average Forward P/E of 23.32, which means EXEL is trading at a premium to the group.
Also, we should mention that EXEL has a PEG ratio of 0.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.68 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.